KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Yasuhiko Matsumori, Shigekazu Kitamura, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Terence Fullerton, Fumihiko Sakai, Takao Takeshima

J Headache Pain 27(1) 66

PMID41761058
PMCIDPMC12961872
DOI10.1186/s10194-026-02290-6
发表日期2026-02-27
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND: The aim of the current analyses of a phase 3 randomized controlled trial conducted in Japan was to assess the long-term safety and effectiveness of rimegepant 75 mg, taken for up to 52 weeks, for the preventive treatment of migraine. METHODS: The study included adults in Japan with a history of 4–18 migraine attacks/month of moderate or severe pain intensity. After 12 weeks’ double-blind treatment with rimegepant 75 mg or placebo every other day, participants took open-label rimegepant 75 mg every other day and additionally as needed on nonscheduled dosing days (maximum one dose of rimegepant 75 mg per calendar day), for up to 40 weeks. Safety assessments included adverse events and hepatic function. Effectiveness endpoints included change in monthly migraine days, medication use, and changes in migraine-related quality of life and disability. RESULTS: Of 496 participants who received double-blind treatment, 458 participants were treated with rimegepant in the open-label-extension phase (mean age 43.9 years, 90.8% female) for a mean of 37.5 weeks. During the open-label extension phase, the most common adverse events were nasopharyngitis (25.1%) and COVID-19 (13.1%); the rate of adverse events leading to rimegepant discontinuation was 1.3% and the rate of serious adverse events was 0.9%. Aminotransferases >3x the upper limit of normal occurred in four (0.9%) participants during the open-label extension phase; none of these participants had concurrent elevations with total bilirubin >2x upper limit of normal. For the open-label extension phase overall, monthly migraine days of any pain intensity reduced by a mean (95% confidence interval [95% CI]) of –4.5 (95% CI –4.8, –4.2) days with 55.4% (95% CI 50.8, 59.9) of participants experiencing ≥50% reductions compared with the observation period. The use of acute treatments for migraine was low through the open-label extension phase. Improvements from baseline in Migraine-Specific Quality-of-Life Questionnaire v2.1, Migraine Disability Assessment (MIDAS), and EQ visual analog scale were observed through the 52-week study. CONCLUSIONS: Sustained effectiveness, with a favorable safety profile, was observed in treatment with rimegepant 75 mg taken up to once daily for up to 52 weeks. TRIAL REGISTRATION: Trial registration Clinicaltrials.gov, NCT05399485. Registered May 27, 2022

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study design, showing 28-day OP, followed by 12-week DBT phase then 40-week OLE phase. DBT, double-blind treatment; EOD, every other day; OLE, open-label extension; OP, observation phase
非 KM Figure
Fig. 2Fig. 2 Disposition of study participants during the OLE phase. OLE rimegepant safety analysis set. DBT, double-blind treatment; OLE, open-label extension. a Participants who took rimegepant in both DBT and OLE phases. b Participants who took placebo in the DBT phase then took rimegepant during the OLE phase
非 KM Figure
Fig. 3Fig. 3 Mean change (95% CI) from OP in MMD of ( A ) any pain intensity and ( B ) moderate or severe pain intensity; according to participants’ randomized assignment in the DBT phase and overall during the OLE phase when all participants were receiving rimegepant. Effectiveness endpoints were assessed for each study month (4-week period), including M1 (Weeks > 0 to ≤ 4) through M3 (Weeks > 8 to ≤ 12) during the DBT phase and M4 (Weeks > 12 to ≤ 16) through M13 (Weeks > 48 to ≤ 52) during the OLE phase. DBT migraine analysis set (OP and M1–M3) and OLE rimegepant migraine analysis set (M4–M13). For additional data, see Table S2 (any pain intensity) and Table S3 (moderate or severe pain intensity). CI, confidence interval; DBT, double-blind treatment; M, month; MMD, monthly migraine days; OLE, open-label extension; OP, observation phase
非 KM Figure
Fig. 4Fig. 4 Percentage of participants (95% CI) with ≥ 50%, ≥ 75%, and 100% reductions from the OP in MMD of ( A ) any pain intensity, and ( B ) moderate or severe pain intensity; according to participants’ randomized assignment in the DBT phase (M1–M3) and overall during the OLE phase (M4–M13) when all participants were receiving rimegepant. Effectiveness endpoints were assessed for each study month (4-week period), including M1 (Weeks > 0 to ≤ 4) through M3 (Weeks > 8 to ≤ 12) during the DBT phase and M4 (Weeks > 12 to ≤ 16) through M13 (Weeks > 48 to ≤ 52) during the OLE phase. DBT migraine analysis set (M1–M3) and OLE rimegepant migraine analysis set (M4–M13). CI, confidence interval; DBT, double-blind treatment; M, month; MMD, monthly migraine days; OLE, open-label extension; OP, observation phase
非 KM Figure
Fig. 5Fig. 5 Mean (95% CI) medication days per month: ( A ) acute migraine-specific medication, and ( B ) acute migraine medication; according to participants’ randomized assignment in the DBT phase and overall during the OLE phase when all participants were receiving rimegepant. Effectiveness endpoints were assessed for each study month (4-week period), including M1 (Weeks > 0 to ≤ 4) through M3 (Weeks > 8 to ≤ 12) during the DBT phase and M4 (Weeks > 12 to ≤ 16) through M13 (Weeks > 48 to ≤ 52) during the OLE phase. DBT migraine analysis set (OP and M1–M3) and OLE rimegepant migraine analysis set (M4–M13). For additional data see Table S4. CI, confidence interval; DBT, double-blind treatment; M, month; OLE, open-label extension; OP, observation phase
非 KM Figure
Fig. 6Fig. 6 Mean change (95% CI) from baseline in ( A ) MSQoL scores, ( B ) MIDAS scores, and ( C ) EQ-VAS scores through the study according to participants’ randomized assignment at the end of the DBT phase (Week 12) and overall at Weeks 24 and 52 of the OLE phase when all participants were receiving rimegepant. Effectiveness endpoints assessed at the end of the DBT phase (Week 12), and at Week 24 and Week 52 of the OLE phase. DBT efficacy analysis set. For additional data see Table S5. BL, baseline; CI, confidence interval; DBT, double-blind treatment; EQ-VAS, EQ visual analog scale; MIDAS, Migraine Disability Assessment; MSQoL, Migraine-Specific Quality-of-Life Questionnaire v2.1; OLE, open-label extension; W, Week
非 KM Figure